Jens Niewöhner

Title: Jens Niewöhner: Innovator in AXL Antibodies

Introduction

Jens Niewöhner is a prominent inventor based in Munich, Germany. He has made significant contributions to the field of biotechnology, particularly in the development of antibodies. His work focuses on monoclonal antibodies that target the AXL receptor tyrosine kinase, which plays a crucial role in various cellular processes.

Latest Patents

Jens Niewöhner holds a patent for AXL antibodies. The present invention refers to antibodies, particularly monoclonal antibodies, which bind to the extracellular domain of the AXL receptor tyrosine kinase and which at least partially inhibit AXL activity. This innovation has the potential to impact therapeutic approaches in treating diseases associated with AXL activity.

Career Highlights

Niewöhner is associated with U3 Pharma GmbH, a company dedicated to advancing biopharmaceuticals. His expertise in antibody development has positioned him as a key figure in the company’s research initiatives. With a focus on innovative solutions, he continues to contribute to the advancement of medical science.

Collaborations

Throughout his career, Jens Niewöhner has collaborated with notable colleagues, including Thore Hettmann and Jens Ruhe. These partnerships have fostered a collaborative environment that enhances the research and development of new therapeutic options.

Conclusion

Jens Niewöhner is a distinguished inventor whose work in AXL antibodies exemplifies innovation in biotechnology. His contributions are paving the way for new treatments and advancements in the medical field.